Biotech Values

[rkrw]

<<<I wonder how much of today’s AH pop came from the Esperion coattails>>>

espr is no doubt a big factor.

1067 potential is as a combo with statins, so upshot is 1067 is something every pharma with a statin presence is looking at, and esp motivated should be any competitor to pfizer. Pfizer has invested a ton in an hdl booster to combine with lipitor. If the hdl drug works as advertised pfe will absolutely own the statin space (more than they already do) if azn, mrk etc don't strike back. If the 1067 data bear out in their arise trial (actual outcomes), agix ample market cap will get much more ample Good chance agix ends up like espr, taken out before long.